MENU
+Compare
BTAI
Stock ticker: NASDAQ
AS OF
Apr 2, 04:59 PM (EDT)
Price
$1.96
Change
+$0.04 (+2.08%)
Capitalization
6.52M

BTAI stock forecast, quote, news & analysis

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company... Show more

Industry: #Biotechnology
BTAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for BTAI with price predictions
Apr 01, 2025

BTAI in upward trend: price may ascend as a result of having broken its lower Bollinger Band on March 31, 2025

BTAI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 45 cases where BTAI's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BTAI's RSI Indicator exited the oversold zone, of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 19 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for BTAI just turned positive on February 28, 2025. Looking at past instances where BTAI's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where BTAI advanced for three days, in of 263 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 28, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on BTAI as a result. In of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BTAI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for BTAI entered a downward trend on March 03, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (13.458). P/E Ratio (0.000) is within average values for comparable stocks, (64.587). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.867). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (2.148) is also within normal values, averaging (251.391).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. BTAI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BTAI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Sarepta Therapeutics (NASDAQ:SRPT), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.19B. The market cap for tickers in the group ranges from 151 to 302.51B. NONOF holds the highest valuation in this group at 302.51B. The lowest valued company is MYMX at 151.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -5%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was -12%. MMIRF experienced the highest price growth at 470%, while IBO experienced the biggest fall at -75%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 59%. For the same stocks of the Industry, the average monthly volume growth was 12% and the average quarterly volume growth was 115%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 84
Price Growth Rating: 71
SMR Rating: 94
Profit Risk Rating: 95
Seasonality Score: -2 (-100 ... +100)
View a ticker or compare two or three
BTAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

a biopharmaceutical company

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
555 Long Wharf Drive
Phone
+1 475 238-6837
Employees
74
Web
https://www.bioxceltherapeutics.com